Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10

LMDXF

LONDON, March 3, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights.

LumiraDx (PRNewsfoto/LumiraDx)

Event:

LumiraDx Fourth Quarter 2021 Financial Results Conference Call

Date:

Thursday, March 10, 2022

Time:

8:00 AM Eastern Time

Live Call/Webcast:

(844) 224-4100 (Domestic), (215) 372-9500 (International)


Conference ID: 5877767


https://investors.lumiradx.com/news-and-events/investor-calendar

A replay of the webcast will be available on the Investor's section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.

About LumiraDx

LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
LumiraDx is based in the UK with more than 1600 employees worldwide.

Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com

Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lumiradx-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-host-quarterly-conference-call-on-march-10-301495001.html

SOURCE LumiraDx